Experts suggest Bharti Airtel, VBL, and PB Fintech as potential stocks for immediate profits due to their bullish trends. Meanwhile, IPCA Labs and Laurus Labs display robust upward trends, making them attractive for short-term investments as well.

Aster DM Healthcare has conducted a significant block deal, worth approximately INR 75.8 crore, selling off over a million shares at around INR 737.8 apiece on the NSE.

Aster DM Healthcare's shares have reached an unprecedented high, indicating a robust bullish trend. The stock's upward momentum is supported by higher highs and lows, a positive RSI reading, and its current position above crucial moving averages. This could suggest continued growth for the company.

Aster DM Healthcare reported a significant increase in Q4 revenue, reaching INR 2361 crores, and EBITDA climbed by 25%, marking a notable growth at INR 517 crores. Shareholders have approved the merger with Quality Care, awaiting final approval from NCLT. The expansion plans include adding 4,445 new beds to their facilities.

Elara Capital raises its target price for Aster DM Healthcare to ₹736, suggesting a potential increase of over 15%. The brokerage maintains a 'Buy' recommendation on the stock.

HSBC remains optimistic about Aster DM Healthcare's growth potential, setting a target price of ₹785, backed by robust Q4 results, talent retention efforts, expansion in Bengaluru, and the upcoming merger with Aster-QCIL in Q1 FY27.

By combining forces with Quality Care, Aster DM is looking to expand its capacity significantly, aiming to have approximately 15,000 hospital beds operational by the fiscal year 2030. This move could potentially position them as a leading healthcare provider in the industry.

Aster DM Healthcare experienced a significant boost in Q4 FY26, reporting a 77.4% increase in net profit for the March 2026 quarter. The specifics of this growth are not fully disclosed due to the nature of the report.

Aster DM Healthcare reported a notable 18% year-on-year increase in Q4 FY26 revenue, reaching INR 1,182 Cr. The company's shareholders also approved the merger with QCIL, resulting in proforma revenues growing by 18% to INR 2,361 Cr.

Aster DM Healthcare's impressive performance has pushed its valuation beyond 'expensive' territory, now categorized as 'very expensive', due to robust returns. Notably, key financial indicators like Price-to-Earnings (P/E) and Price-to-Book Value (P/BV) surpass both industry averages and historical benchmarks.

Aster DM Healthcare is set to release their fourth-quarter and full-year 2026 financial results on April 30, 2026. The board will review both audited standalone and consolidated financial statements for the fiscal year ending March 31, 2026.

Aster DM Healthcare has purchased a 26% share in Oyster Green Hybrid for INR 5.8 crore, with plans for Oyster to construct a 18 MWp solar power plant in Kerala. Aster DM will buy all the electricity generated from this project.

HSBC has upgraded Aster DM Healthcare to 'Buy', predicting a target price of ₹755 due to optimistic Q4FY26 expectations. This positive outlook is driven by growth in elective procedures, capital expenditure expansion, and effective management of margin impacts from new units.

Aster DM Healthcare has allocated a ₹96 crore investment to enhance their women and kid's healthcare facilities, aiming to boost capacity and elevate care quality for expectant mothers and young patients.

Aster DM significantly boosts its Whitefield Hospital's capacity with a Rs 96 crore investment, increasing the number of beds to 539. The expansion includes a 159-bed women and children facility providing specialized maternity care, neonatal intensive care, and pediatric services.

The stocks of Apollo Pipe, Aster DM, and NLC India have seen bullish breakouts, indicating potential gains. Investors may consider buying at levels of around ₹405 for Apollo Pipe, ₹680 for Aster DM, and ₹273 for NLC India. Target prices are set at ₹470, ₹730, and ₹292 respectively, with stop-loss points to limit potential losses if the market takes a turn.